Acquisition and Disposition - Additional Information (Details)		3 Months Ended				9 Months Ended
	Sep. 08, 2023 USD ($) item $ / shares shares	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 26, 2024 USD ($)	Mar. 01, 2024 USD ($)	Dec. 31, 2023 USD ($)
Surface Acquisition
Cash consideration									$ 170,000,000.0
Pretax profit (loss)		$ (10,751,000)			$ (40,021,000)	$ 79,203,000	$ (158,619,000)
TSA receivables, net		31,241,000				31,241,000
TSA payables and other accrued liabilities		33,637,000				33,637,000
Additional consideration									17,800,000
Goodwill										$ 943,000
Net impairment charge						6,772,000
Contingent consideration, current										$ 3,300,000
Novartis Institutes
Surface Acquisition
Impairment charge				$ 10,600,000
CIMERLI Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Surface Acquisition
Cash consideration				187,800,000					170,000,000.0
Gain on sale transaction				153,600,000
Transaction costs				7,200,000
Pretax profit (loss)		(1,200,000)			6,900,000	6,200,000	5,700,000
TSA receivables, net		27,800,000				27,800,000
TSA payables and other accrued liabilities		30,400,000				30,400,000
Additional consideration									$ 17,800,000
Retention bonus		4,700,000				4,700,000
Income under TSA		500,000				1,600,000
YUSIMRY Sale
Surface Acquisition
Reimbursable costs		500,000				500,000
YUSIMRY Sale | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Surface Acquisition
Cash consideration			$ 40,000,000.0					$ 40,000,000.0
Inventory purchase commitments								$ 17,000,000.0
Gain on sale transaction			22,900,000
Transaction costs incurred			$ 1,000,000.0
Transaction costs unpaid		800,000				800,000
Pretax profit (loss)		(200,000)			$ (2,000,000.0)	1,300,000	$ (12,100,000)
TSA receivables, net		3,400,000				3,400,000
TSA payables and other accrued liabilities		$ 3,200,000				$ 3,200,000
Surface Acquisition
Surface Acquisition
Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares	0.1960
Share price | $ / shares	$ 5.2831
Contingent value right per share | item	1
Contingent value rights payment period	10 years
Goodwill	$ 0
Business Combination, Number of Out Licensed Partnership Program | item	2
Fair value of the contingent consideration				3,800,000
Contingent consideration, current				0
Surface Acquisition | Novartis Institutes
Surface Acquisition
Net impairment charge				$ 6,800,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]				Selling, General and Administrative Expense
Impairment charge				$ 10,600,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]				Selling, General and Administrative Expense
Surface Acquisition | Surface GSK Agreement
Surface Acquisition
Milestone and royalty based CVR payments (as percent)	70.00%
Surface Acquisition | Surface's SRF114 proprietary drug product candidate
Surface Acquisition
Upfront payment based CVR payments (as percent)	25.00%
Surface Acquisition | Surface's SRF388 proprietary drug product candidate
Surface Acquisition
Upfront payment based CVR payments (as percent)	50.00%